scholarly journals The Effect of Phosphate Binders in Patients With End Stage Kidney Disease Undergoing Hemodialysis: a Prospective Observational Study

2021 ◽  
Author(s):  
Jie Ge ◽  
Niroj Mali ◽  
WenXing Fan
Keyword(s):  
Prospective Observational Study ◽  
Adverse Reactions ◽  
Effective Rate ◽  
Lanthanum Carbonate ◽  
Serum Phosphorus ◽  
Phosphate Binders ◽  
Maintenance Hemodialysis ◽  
Carbonate Group ◽  
The Difference ◽  
Group Serum

Abstract To compare the clinical efficacy of sevalamer carbonate and lanthanum carbonate in chronic hemodialysis patients. This prospective observational study included 80 patients randomly divided into two groups were followed from December 2019 to December 2020. After 12 months of maintenance hemodialysis treatment with sevalamer carbonate or lanthanum carbonate, serum phosphorus, serum calcium, alkaline phosphatase(ALP), parathyroid hormone (iPTH), low-density lipoprotein(LDL), hemoglobin(HGB), triglycerides(TG) and albumin(ALB) were evaluated. The adequacy of dialysis, the effective rate of treatment and the incidence of adverse reactions were compared as well. After treatment, In lanthanum carbonate group, serum phosphorus and iPTH decreased and albumin increased, the difference was significant(P < 0.05). In sevalamer carbonate group, serum phosphorus and LDL decreased and albumin increased after treatment, the difference was significant(P < 0.05). There was no significant difference in the dialysis adequacy and total effective rate between the two groups (P>0.05). However, the incidence of gastrointestinal adverse reactions in the sevalamer carbonate group was lower than in the lanthanum carbonate group and the difference was significant (P < 0.05). The two phosphate binders are safe and effective for the treatment of hyperphosphatemia in patients with ESKD undergoing maintenance hemodialysis. Nevertheless, sevalamer carbonate seems to be superior with lowering the incidence of gastrointestinal adverse reactions and improving lipid metabolism.

scholarly journals The Effect of Phosphate Binders in Patients With End Stage Kidney Disease Undergoing Hemodialysis: a Prospective Cohort Study

2021 ◽  
Author(s):  
Jie Ge ◽  
Niroj Mali ◽  
WenXing Fan ◽  
JingYuan Ma
Keyword(s):  
Adverse Reactions ◽  
Effective Rate ◽  
Lanthanum Carbonate ◽  
Serum Phosphorus ◽  
Phosphate Binders ◽  
Maintenance Hemodialysis ◽  
Carbonate Group ◽  
Significant Difference ◽  
The Difference ◽  
Group Serum

Abstract Background: To compare the clinical efficacy of sevalamer carbonate and lanthanum carbonate in chronic hemodialysis patients. Methods: This prospective observational study included 76 patients with follow-up from September 2019 to December 2020. After 15 months of maintenance hemodialysis treatment with sevalamer carbonate or lanthanum carbonate, serum phosphorus, serum calcium, alkaline phosphatase(ALP), parathyroid hormone (iPTH), low-density lipoprotein(LDL), hemoglobin(HGB), triglycerides(TG) and albumin(ALB) were evaluated. The adequacy of dialysis, the effective rate of treatment and the incidence of adverse reactions were compared as well. Results: After treatment, In lanthanum carbonate group, serum phosphorus and iPTH decreased and albumin increased, the difference was significant(P < 0.05). In sevalamer carbonate group, serum phosphorus and LDL decreased and albumin increased after treatment, the difference was significant(P < 0.05). There was no significant difference in the dialysis adequacy and total effective rate between the two groups (P>0.05). However, the incidence of adverse reactions in the sevalamer carbonate group was lower than in the lanthanum carbonate group and the difference was significant (P < 0.05). Conclusion: The two phosphate binders are safe and effective for the treatment of hyperphosphatemia in patients with ESKD undergoing maintenance hemodialysis. Nevertheless, sevalamer carbonate seems to be superior with lowering the incidence of gastrointestinal adverse reactions and improving lipid metabolism.

scholarly journals Implementation and effectiveness of an intensive education program on phosphate control among hemodialysis patients: a non-randomized, single-arm, single-center trial

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Jinmei Yin ◽  
Jun Yin ◽  
Rongli Lian ◽  
Peiqiu Li ◽  
Jing Zheng
Keyword(s):  
Education Program ◽  
Hemodialysis Patients ◽  
Serum Phosphorus ◽  
Phosphate Binders ◽  
Maintenance Hemodialysis ◽  
Single Center ◽  
Clinical Trial Registry ◽  
Before And After ◽  
Intensive Education ◽  
Phosphate Control

Abstract Background Hyperphosphatemia is a common complication in patients on maintenance hemodialysis. Patients’ adherence to phosphorus control can be improved by consistent education. However, few studies have focused on the model construction and effects of health education on phosphate control for hemodialysis patients. Objective To develop an intensive education program focusing on phosphate control among hemodialysis patients and to analyze the effectiveness of this program. Design A non-randomized, single-arm, single-center trial lasting for 6 months. Setting This program was conducted in a hemodialysis center in a teaching hospital in Zhuhai, China. Participants Patients on maintenance hemodialysis with hyperphosphatemia. Methods An intensive hyperphosphatemia control education program lasting for 6 months was conducted among 366 hemodialysis patients applying the First Principles of Instruction model, which focused on mastering four stages: (a) activation of prior experience, (b) demonstration of skills, (c) application of skills and (d) integration of these skills into real-world activities. The controlled percentage of serum phosphorus, knowledge of hyperphosphatemia, and adherence to phosphate binders before and after the education program were assessed. Results The proportion of controlled serum phosphorus was significantly increased from 43.5 to 54.9% (P<0.001). The scores on the knowledge of phosphate control were improved significantly from 59.0 ± 18.9 to 80.6 ± 12.4 (P < 0.001). The proportion of high adherence to phosphate binders was increased dramatically from 21.9 to 44.5% (P < 0.001). Conclusion The intensive education program can effectively improve serum phosphorus, knowledge of hyperphosphatemia, and adherence to phosphate binders among hemodialysis patients. Trial registration Chinese Clinical Trial Registry, ChiCTR2100042017. Retrospectively registered January 12th, 2021.

scholarly journals Clinical Observation of Zhuang Medicine Crystal Sugar Ye’An Decoction in Treating Senile Skin Pruritus and Its Effects on Serum IgE

2020 ◽  
Vol 4 (6) ◽  
Author(s):  
Yun Zhang ◽  
Yuying Lan
Keyword(s):  
Adverse Reactions ◽  
Clinical Observation ◽  
Skin Lesions ◽  
Effective Rate ◽  
Inflammatory Factors ◽  
Control Group ◽  
Observation Group ◽  
Serum Ige ◽  
The Difference ◽  
Lesion Severity

Objective: To discuss the specific application of Zhuang Medicine Crystal Sugar Ye’An Decoction in senile skin pruritus and its effects on serum IgE detection level. Methods: 90 patients with senile skin pruritus admitted to our hospital from February 2019 to April 2020 were randomly grouped. The general treatment effect, itching, secondary skin lesion severity, serum IL-6, IgE level and adverse reactions between 45 patients treated with Chlorcyclizine Hydrochloride Tablets (The control group) and 45 patients treated with Crystal Sugar Ye’An Decoction were compared. Results: The total effective rate of the treatment in the observation group was 93.33%, much higher than that in the control group, 75.56%. The difference was verified and statistically significant (P<0.05). Before the treatment, the itching area, frequency, duration and severity of secondary skin lesions were at the same level (P>0.05). After the treatment, the above data were all reduced, and the reduction of the observation group was more significant than that of the control group, indicating the difference was statistically significant (P<0.05). Before the treatment, there was no difference in serum IL-6 and IgE test data between the two groups (P>0.05). After the treatment, the tendency all declined, and that of the observation group was more obvious, indicating the difference was statistically significant (P<0.05). During the experiment, no obvious adverse reactions were observed in both groups. Conclusion: In the treatment of patients with senile pruritus, the application of Zhuang Medicine Crystal Sugar Ye’An Decoction is not only safe and reliable, but can promote the improvement of patients’ symptoms, adjust the level of inflammatory factors, and enhance clinical efficacy.

scholarly journals Analysis of Clinical Effect of Treating Arrhythmia with Stable Heart Granules

2013 ◽  
Vol 2 ◽  
pp. 7
Author(s):  
Li Liu
Keyword(s):  
Clinical Practice ◽  
Adverse Reactions ◽  
Clinical Effect ◽  
Total Effective Rate ◽  
Effective Rate ◽  
Control Group ◽  
Observation Group ◽  
The Difference ◽  
And Control ◽  
Group Observation

<p><strong>Objective: </strong>To study the clinical effect on the treatment of cardiac arrhythmia, and further guide the clinical treatment. <strong>Method: </strong>From January 2011 to January 2013, 100 patients with arrhythmia were randomly divided into observation group and control group with 50 cases in each group. Observation group patients given oral Stable heart granule treatment, while control group was treated with oral propafenone treatment. The therapeutic effect and adverse reactions of the two groups were observed and compared. <strong>Results: </strong>The total effective rate of the observation group was higher than control group and incidence of adverse reactions was lower than control group, the difference was statistically significant, <em>p</em> &lt; 0.05. The use of stable heart particles in the treatment of arrhythmia produce significant effect. <strong>Conclusion: </strong>Clinical effect for Stable heart granule on arrhythmia was significant and should widely entrenched in clinical practice.</p>

scholarly journals Clinical effect of decitabine in the treatment of myelodysplastic syndrome and influencing factors

2020 ◽  
Vol 36 (5) ◽  
Author(s):  
Tangxia Liu ◽  
Jing Wang ◽  
Chunmei Li ◽  
Lingzhi Jia
Keyword(s):  
Myelodysplastic Syndrome ◽  
Influencing Factors ◽  
Adverse Reactions ◽  
Clinical Effect ◽  
Progression Free Survival ◽  
Effective Rate ◽  
Good Effect ◽  
Conventional Chemotherapy ◽  
Traditional Group ◽  
The Difference

Objective: To analyze the effect of decitabine combined with conventional chemotherapy on myelodysplastic syndrome (MDS) and its influencing factors. Methods: Eighty patients with MDS who were admitted to our hospital were selected by this study between February 2017 and February 2018. The selected patients were divided into a traditional group (CAG/DA scheme) and the combined group (DAC combined with CAG/DA scheme) according to the random number table method, 40 each. The clinical treatment effects of the two groups were compared, and the influencing factors of the effect were analyzed. Results: After four courses of treatment, the difference in the total effective rate between the two groups were statistically significant (P<0.05); the difference in the incidence of adverse reactions and in the overall survival (OS) rate between the two groups were not statistically significant (P>0.05). However, the progression free survival (PFS) rate of the combined group was significantly higher compared with the traditional group (P<0.05); the Hb level, WHO stage and and karyotype of the patients before treatment had significant influence on the treatment effect (P<0.05). Conclusion: DAC in combination with conventional chemotherapy has good effect in the treatment of MDS, and it will not increase adverse reactions. In addition to treatment scheme, the influencing factors of the effect of treatment for MDS also include Hb, WHO stage and karyotype. doi: https://doi.org/10.12669/pjms.36.5.2289 How to cite this:Liu T, Wang J, Li C, Jia L. Clinical effect of decitabine in the treatment of myelodysplastic syndrome and influencing factors. Pak J Med Sci. 2020;36(5):1084-1088. doi: https://doi.org/10.12669/pjms.36.5.2289 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

scholarly journals Efficacy of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Management of Malignant Ascites

2020 ◽  
Author(s):  
Jie Jiao ◽  
Chengzhen Li ◽  
Guanying Yu ◽  
Lei Zhang ◽  
Xiaoyan Shi ◽  
...  
Keyword(s):  
Intraperitoneal Chemotherapy ◽  
Adverse Reactions ◽  
Total Effective Rate ◽  
Malignant Ascites ◽  
Effective Rate ◽  
Control Group ◽  
Observation Group ◽  
Short Term ◽  
Significant Difference ◽  
The Difference

Abstract Objective: The purpose of this study is to compare the difference of clinical efficacy between conventional intraperitoneal chemotherapy and HIPEC, so as to explore the clinical application value and advantages of HIPEC.Design: A retrospective analysis was conducted on 80 patients with malignant ascites admitted to our hospital from June 2017 to June 2019. The general clinical data and qualitative data of the treatment results of 80 patients with malignant ascites were processed by SPSS19.0 using χ2 test and quantitative data were processed by t test. P <0.05, statistical data can be considered statistically significant.Results: 1. There was no significant change in vital signs and temperature in the observation group during the treatment, and the difference was not statistically significant 2. The short-term total effective rate of patients in the observation group was 91.11%, and the short-term total effective rate of the patients in the control group was 40%.3. There was no significant difference in the incidence of adverse reactions between the two groups of patients.Conclusion: Intraperitoneal hyperthermic chemotherapy combined with intravenous chemotherapy can significantly control malignant ascites, and has small adverse reactions, which is worthy of clinical promotion and application.

scholarly journals Impact of Survival Rate and Safety Analysis of Concurrent Chemoradiotherapy in Patients with Recurrent Cervical Cancer

2020 ◽  
Vol 3 (6) ◽  
Author(s):  
Guohua Liang ◽  
Yajun Zhu ◽  
Qianqian Yu ◽  
Wangsheng Tian
Keyword(s):  
Cervical Cancer ◽  
Survival Rate ◽  
Adverse Reactions ◽  
Concurrent Chemoradiotherapy ◽  
Effective Rate ◽  
Control Group ◽  
Observation Group ◽  
Recurrent Cervical Cancer ◽  
The Difference ◽  
Cellular Immune

Objective: To investigate the effect of concurrent chemoradiotherapy on the survival rate and safety of patients with recurrent cervical cancer. Methods: A total of 107 patients with recurrent cervical cancer who were treated in our hospital from March 2016 to January 2019 were retrospectively analyzed and randomly divided into the control group (n = 53) and the observation group (n = 54) and treated conventionally. On this basis, the control group was treated with radiotherapy, and the observation group was treated with concurrent radiotherapy and chemotherapy. The clinical efficacy, cellular immune index, survival rate and rate of adverse reactions were compared between the two groups. Results: Compared with the total effective rate of 79.25% in the control group, the observation group was 94.44%, and the difference was statistically significant(P<0.05). After treatment, the levels of NK, CD3+, and CD4+ in the two groups were higher than before the treatment, and the observation group was higher than the control group. The difference was statistically significant (P<0.05). Compared with the adverse reaction rate of 18.87% in the control group, the observation group was 11.11%, but the difference was not statistically significant (P>0.05). Conclusion: Concurrent chemoradiotherapy for patients with recurrent cervical cancer has a significant effect, which not only can effectively improve the cellular immune index and the survival rate of patients, but also have high safety.

scholarly journals Implementation and Effectiveness of an Intensive Education Program on Phosphate Control Among Hemodialysis Patients: A Non-Randomized, Single-Arm, Single-Center Trial

2021 ◽  
Author(s):  
Jinmei Yin ◽  
Jun Yin ◽  
Rongli Lian ◽  
Peiqiu Li ◽  
Jing Zheng
Keyword(s):  
Education Program ◽  
Hemodialysis Patients ◽  
Serum Phosphorus ◽  
Phosphate Binders ◽  
Maintenance Hemodialysis ◽  
Single Center ◽  
Clinical Trial Registry ◽  
Before And After ◽  
Intensive Education ◽  
Phosphate Control

Abstract Background: Hyperphosphatemia is a common complication in patients on maintenance hemodialysis. Patients’ adherence to phosphorus control can be improved by consistent education. However, few studies have focused on the model construction and effects of health education on phosphate control for hemodialysis patients.Objective: To develop an intensive education program focusing on phosphate control among hemodialysis patients and to analyze the effectiveness of this program.Design: A non-randomized, single-arm, single-center trial lasting for 6 months.Setting: This program was conducted in a hemodialysis center in a teaching hospital in Zhuhai, China.Participants: Patients on maintenance hemodialysis with hyperphosphatemia.Methods: A intensive hyperphosphatemia control education program lasting for 6 months was conducted among 366 hemodialysis patients applying the First Principles of Instruction model, which focused on mastering four stages: (a) activation of prior experience, (b) demonstration of skills, (c) application of skills and (d) integration of these skills into real-world activities. The controlled rate of serum phosphorus, knowledge of hyperphosphatemia, and adherence to phosphate binders before and after the education program were assessed. Results: The controlled rate of serum phosphorus was significantly increased from 43.5% to 54.9% (P＜0.001). The scores of the patients’ knowledge of phosphate control were improved significantly from 59.10±12.90 to 80.98±14.82 (P<0.001). The percentage of high adherence to phosphate binders was increased dramatically from 21.9% to 44.5% (P<0.001). Conclusion: The intensive education program can effectively improve the controlled rate of serum phosphorus, knowledge of hyperphosphatemia, and adherence to phosphate binders among hemodialysis patients.Trial registration: Chinese Clinical Trial Registry, ChiCTR2100042017. Registered 12 January 2021 - Retrospectively registered, http://www.chictr.org.cn/login.aspx

scholarly journals Efficacy of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Management of Malignant Ascites

2020 ◽  
Author(s):  
Jie Jiao ◽  
Chengzhen Li ◽  
Guanying Yu ◽  
Lei Zhang ◽  
Xiaoyan Shi ◽  
...  
Keyword(s):  
Intraperitoneal Chemotherapy ◽  
Adverse Reactions ◽  
Total Effective Rate ◽  
Malignant Ascites ◽  
Effective Rate ◽  
Observation Group ◽  
Short Term ◽  
Intraperitoneal Hyperthermic Chemotherapy ◽  
Hyperthermic Chemotherapy ◽  
The Difference

Abstract Objective: The purpose of this study is to compare the difference of clinical efficacy between conventional intraperitoneal chemotherapy and HIPEC, so as to explore the clinical application value and advantages of HIPEC. Design: A retrospective analysis was conducted on 80 patients with malignant ascites admitted to our hospital from June 2017 to June 2019. The general clinical data and qualitative data of the treatment results of 80 patients with malignant ascites were processed by SPSS19.0 using χ2 test and quantitative data were processed by t test. P <0.05, statistical data can be considered statistically significant. Results: 1. There was no significant change in vital signs and temperature in the observation group during the treatment, and the difference was not statistically significant 2. The short-term total effective rate of patients in the observation group was 91.11%, and the short-term total effective rate of the patients in the control group was 40%. 3. There was no significant difference in the incidence of adverse reactions between the two groups of patients. Conclusion: Intraperitoneal hyperthermic chemotherapy combined with intravenous chemotherapy can significantly control malignant ascites, and has small adverse reactions, which is worthy of clinical promotion and application. Key words: efficacy; malignant ascites; intraperitoneal hyperthermic chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document